Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease

Fabry Disease ◽

Replacement Therapy ◽

Agalsidase Beta ◽

Enzyme Replacement ◽

Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme®) to Agalsidase Alfa (Replagal®)

10.1007/8904_2014_304 ◽

2014 ◽

Cited By ~ 1

Author(s):

Kazuya Tsuboi ◽

Hiroshi Yamamoto ◽

Fuji Somura ◽

Hiromi Goto

Keyword(s):

Adverse Events ◽

Fabry Disease ◽

Replacement Therapy ◽

Agalsidase Beta ◽

Successful Management ◽

Enzyme Replacement ◽

Agalsidase Alfa ◽

Severe Adverse Events

Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta

10.1016/j.ymgme.2008.07.002 ◽

2008 ◽

Vol 95 (1-2) ◽

pp. 114-115 ◽

Cited By ~ 15

Author(s):

Atul Mehta ◽

Michael Beck ◽

Christoph Kampmann ◽

Andrea Frustaci ◽

Dominique P. Germain ◽

...

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Agalsidase Beta ◽

Enzyme Replacement ◽

An open-label, switchover trial to assess the safety and efficacy of agalsidase beta in patients with Fabry disease treated with agalsidase alfa enzyme replacement therapy

10.1016/j.ymgme.2013.12.217 ◽

2014 ◽

Vol 111 (2) ◽

pp. S90

Author(s):

Sarah Richards ◽

Dawn Laney ◽

Muhammad A. Pervaiz ◽

Suma Shankar

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Agalsidase Beta ◽

Open Label ◽

Safety And Efficacy ◽

Enzyme Replacement ◽

Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa

Journal of the Chinese Medical Association ◽

10.1016/j.jcma.2013.11.006 ◽

2014 ◽

Vol 77 (4) ◽

pp. 190-197 ◽

Cited By ~ 7

Author(s):

Hsiang-Yu Lin ◽

Yu-Hsiu Huang ◽

Hsuan-Chieh Liao ◽

Hao-Chuan Liu ◽

Ting-Rong Hsu ◽

...

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Agalsidase Beta ◽

Enzyme Replacement ◽

Clinical Observations ◽

Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study

10.1016/j.ymgme.2011.11.174 ◽

2012 ◽

Vol 105 (2) ◽

pp. S64-S65

Author(s):

Michael West ◽

Daniel Bichet ◽

Robin Casey ◽

Joe Clarke ◽

Sandra Sirrs ◽

...

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Agalsidase Beta ◽

Enzyme Replacement ◽

Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease

European Journal of Obstetrics & Gynecology and Reproductive Biology ◽

10.1016/j.ejogrb.2009.01.007 ◽

2009 ◽

Vol 144 (1) ◽

pp. 92-93 ◽

Cited By ~ 21

Author(s):

G. Kalkum ◽

D. Macchiella ◽

J. Reinke ◽

H. Kölbl ◽

M. Beck

Keyword(s):

Pregnant Women ◽

Fabry Disease ◽

Replacement Therapy ◽

Enzyme Replacement ◽

Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan

10.1016/j.ymgme.2019.02.005 ◽

2019 ◽

Vol 126 (4) ◽

pp. 448-459 ◽

Cited By ~ 5

Author(s):

Hiroaki Sasa ◽

Munehiko Nagao ◽

Koichi Kino

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Enzyme Replacement ◽

Agalsidase Alfa ◽

Post Marketing Surveillance ◽

Post Marketing

Burden of Fabry disease in young patients (≤30 years of age) who were initiated on enzyme replacement therapy with agalsidase beta: a Fabry Registry analysis

10.1016/j.ymgme.2016.11.151 ◽

2017 ◽

Vol 120 (1-2) ◽

pp. S65-S66

Author(s):

Robert J. Hopkin ◽

Eva Brand ◽

Ulla F. Rasmussen ◽

Dominique P. Germain ◽

Nathalie Guffon ◽

...

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Young Patients ◽

Agalsidase Beta ◽

Enzyme Replacement ◽

Registry Analysis

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy

Drug Design Development and Therapy ◽

10.2147/dddt.s102761 ◽

2016 ◽

pp. 1771 ◽

Cited By ~ 9

Author(s):

Ozlem Goker-Alpan ◽

Nicola Longo ◽

Marie McDonald ◽

Suma Shankar ◽

Raphael Schiffmann ◽

...

Keyword(s):

Clinical Trial ◽

Fabry Disease ◽

Replacement Therapy ◽

Open Label ◽

Enzyme Replacement ◽

Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease

Expert Opinion on Investigational Drugs ◽

10.1517/13543784.11.6.851 ◽

2002 ◽

Vol 11 (6) ◽

pp. 851-858 ◽

Cited By ~ 14

Author(s):

Michael Beck

Keyword(s):

Fabry Disease ◽

Replacement Therapy ◽

Enzyme Replacement ◽